Type 2 Diabetes Drug Pipeline Analysis Report 2025

According to the Centers for Disease Control and Prevention (CDC), 38.6 million individuals, accounting for 11.6% of the entire United States population are affected by diabetes. Out of this, approximately 8.7 million are undiagnosed. Over 95% of people with diabetes have type 2 diabetes. Moreover, diabetes is a major cause of blindness, kidney failure as well as heart attacks. Hence, there has been significant emphasis on developing effective type 2 diabetes drugs to manage the condition effectively.

Report Coverage

The Type 2 Diabetes Pipeline Report by the publisher gives comprehensive insights into type 2 diabetes emerging drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development. The type 2 diabetes report assessment includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on type 2 diabetes.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing type 2 diabetes pipeline development activities are covered in this report.

Type 2 Diabetes Drug Pipeline Outlook

Type 2 diabetes is a chronic condition which affects the glucose synthesis in the body, resulting in high blood sugar levels. It is also known as adult-onset diabetes and is more common than type 1 diabetes. it leads to excessive blood sugar levels in the blood and may cause circulatory, nervous and immune system disorders as well.

Type 2 diabetes is more common in adults. It is caused by insulin resistance and the inability of the pancreas to produce enough insulin to manage blood sugar levels. Common symptoms include increased thirst, frequent urination urge, surge in hunger levels, blurred vision, unintended weight loss, tingling sensation or numbing in feet or hands. Having high-fat accumulation around the abdomen or hips, and obesity are some of the major risk factors for type 2 diabetes. As a result, lifestyle modifications such as frequent exercise, and dietary changes are mostly advised treatments.

Type 2 diabetes drugs can be both oral as well as injectable. Oral drugs include several drug classes like Biguanides (metformin), Sulfonylureas (Glipizide, Glyburide, Glimepiride), and others. GLP-1 receptor agonists (a part of injectable medications) are gaining significant popularity in the market. Several type 2 diabetes drug candidates are being developed by several prominent healthcare and pharmaceutical companies. There is an influx of investment to combat the rising fatalities associated with type 2 diabetes across the globe.

Type 2 Diabetes - Drug Pipeline Therapeutic Assessment

This section of the type 2 diabetes report covers the analysis of type 2 diabetes drugs based on various segmentations such as:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The type 2 diabetes clinical assessment report covers 50+ drug analyses based on drug classes:

• Biguanides
• Sulfonylureas
• Meglitinides
• Thiazolidinediones (TZDs)
• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
• Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
• Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors
• Alpha-Glucosidase Inhibitors

By Route of Administration

The type 2 diabetes pipeline insight report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Type 2 Diabetes - Pipeline Assessment Segmentation, By Phases

The type 2 diabetes report assessment covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials conducted, with over 1,514 drugs in the pipeline.

Type 2 Diabetes - Pipeline Assessment Segmentation, By Drug Class

The drug class categories covered under type 2 diabetes pipeline analysis include Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones (TZDs), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, and Alpha-Glucosidase Inhibitors. Glucagon-like Peptide-1 (GLP-1) receptor agonists stimulate insulin release and prevent glucagon release, resulting in satiated feeling. Drugs belonging to this drug class are gaining popularity. Common examples include Liraglutide and Semaglutide among others.

The type 2 diabetes pipeline report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.

Type 2 Diabetes Clinical Trials Assessment - Competitive Dynamics

The report for the type 2 diabetes pipeline insight covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in type 2 diabetes clinical trials:

• Eli Lilly and Company
• Takeda Pharmaceutical Industries, Ltd.
• Sanofi SA
• Novo Nordisk A/S
• GSK PLC
• Others

Type 2 Diabetes - Pipeline Drugs Profile

Afrezza®

Afrezza, designed for type 2 diabetes treatment, is being evaluated in the INHALE-1 trial. The study evaluates its efficacy against insulin analog injections. This type 2 diabetes emerging drug is particularly being investigated for pediatric patients. Sponsored by Mannkind Corporation, INHALE-1 is a 26-week Primary Treatment Phase, randomized clinical trial.

XW-004

Sciwind Biosciences (Sciwind) is developing XW-004 for type 2 diabetes, obesity as well as nonalcoholic steatohepatitis (NASH). It is a glucagon-like peptide 1 receptor (GLP1R) oral drug developed using polypeptide or recombinant protein preparation platform technology.

Investigational Tirzepatide (LY3298176)

Eli Lilly and Company’s Tirzepatide is under investigation for its efficacy and safety in obese type 2 diabetes participants who are on metformin. Currently in phase 3 of an interventional study, enrolling over 13,000 people, this trial is likely to be completed by June 2025.

Reasons To Buy This Report

The Type 2 Diabetes Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for type 2 diabetes. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into type 2 diabetes collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.

Key Questions Answered in the Type 2 Diabetes - Pipeline Assessment Report

• What is the current landscape of type 2 diabetes pipeline drugs?
• Which companies/institutions are developing type 2 diabetes drug candidates?
• How many phase II drugs are currently present in type 2 diabetes pipeline drugs?
• Which company is leading the type 2 diabetes pipeline development activities?
• What is the current type 2 diabetes therapeutic assessment?
• What are the opportunities and challenges present in the type 2 diabetes drug pipeline landscape?
• What is the efficacy and safety profile of type 2 diabetes pipeline drugs?
• Which companies/institutions are involved in type 2 diabetes collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in type 2 diabetes?

This product will be delivered within 3-5 business days.